Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Recruiting1
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

recruiting133%
not_yet_recruiting133%
withdrawn133%

Recent Activity

1 active trials
Showing 3 of 3
not_yet_recruitingphase_3

Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)

NCT07554573
recruitingphase_1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

NCT04732065
withdrawnphase_2

Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma

NCT04485026

Clinical Trials (3)

Showing 3 of 3 trials
NCT07554573Phase 3

Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)

Not Yet Recruiting
NCT04732065Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Recruiting
NCT04485026Phase 2

Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3